Healthcare Industry News: Medarex
News Release - January 3, 2006
Genmab Appoints Annarie Lyles as Head of Business DevelopmentCOPENHAGEN, Denmark, Jan. 3 (HSMN NewsFeed) -- Genmab A/S (CSE: GEN ) announced today the appointment of Annarie Lyles, Ph.D. as Head of Business Development with effect from January 1, 2006. Dr. Lyles was previously appointed Vice President, Business Development at Genmab in June 2005.
Dr. Lyles replaces Dr. Ernst Schweizer, who has retired from his position as Head of Business Development. Dr. Schweizer remains a member of the Genmab Board of Directors.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit http://www.genmab.com.
This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
UltiMAb® is a registered trademark of Medarex, Inc.
Genmab®; HuMax®; HuMax-CD4(TM) and the Y-shaped Genmab logo are all trademarks of Genmab A/S.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.